Adjuvant Chemotherapy for Gastric Cancer may Worsen Prognosis in Elderly Women: Retrospective Analysis of Individual Patient Data from the CLASSIC Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Adjuvant capecitabine and oxaliplatin (CapeOX) chemotherapy for gastric cancer showed unexpected poor outcomes in older women with high serum albumin. Baseline characteristics like tumor stage and lymph node status also influence CapeOX efficacy.
Area Of Science
- Oncology
- Gastroenterology
- Clinical Trials
Background
- Gastric cancer remains a significant global health challenge.
- Adjuvant chemotherapy aims to improve survival after primary tumor resection.
- Capecitabine and oxaliplatin (CapeOX) is a common adjuvant chemotherapy regimen.
Purpose Of The Study
- To identify prognostic factors interacting with the treatment effect of capecitabine and oxaliplatin (CapeOX) in gastric cancer patients.
- To analyze individual patient data from the CLASSIC study (NCT00411229).
- To refine adjuvant chemotherapy strategies based on patient characteristics.
Main Methods
- Individual patient data from the CLASSIC study were analyzed.
- Cox proportional hazards model used for stepwise variable selection.
- Comparison between 519 CapeOX-treated and 514 untreated patients.
Main Results
- Older women (≥55 years) with serum albumin ≥4.0 g/dL showed poor outcomes with CapeOX.
- Serum albumin <4.0 g/dL in untreated patients significantly impacted survival.
- Tumor stage (T≥T3) and lymph node status (N<N2) indicated limited DFS improvement with CapeOX.
Conclusions
- Findings suggest CapeOX may not benefit all gastric cancer patients.
- Patient baseline characteristics, including age, albumin, tumor stage, and nodal status, are crucial for treatment decisions.
- Further research is needed to personalize adjuvant chemotherapy strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...